Frederiksberg Hospital

At Frederiksberg Hospital, clinical trials in cardiovascular diseases focus on heart failure prevention and reducing the risk of major heart-related events. The research is centered on evaluating new treatment combinations that may better protect patients at elevated cardiovascular risk.

• Prevention of heart failure and cardiovascular death
• Testing new approaches to lower risk in high-risk patients
• Assessing treatment effectiveness for long-term heart protection

This work supports efforts to improve outcomes for people who may be vulnerable to serious cardiac complications.

The site is active in immune system diseases and musculoskeletal diseases, with trials in psoriatic arthritis and axial spondyloarthritis. These studies are designed to better control inflammation, ease joint and axial symptoms, and improve daily functioning for people living with chronic inflammatory conditions.

• Psoriatic arthritis and active psoriatic arthritis
• Axial spondyloarthritis and axial disease
• Evaluating new therapies to reduce inflammation and symptoms

Research at Frederiksberg Hospital also includes imaging-based assessment of inflammatory burden, helping to refine how treatment benefit is understood in rheumatic disease.

In the area of psychiatry and psychology, the Lab of Neuropsychiatry is involved in trials addressing schizophrenia and alcohol use disorder. The main goal is to explore whether new treatment strategies can help reduce alcohol consumption and support better management of complex mental health needs.

• Schizophrenia with alcohol use disorder
• Improving management of co-occurring mental health and substance use problems
• Testing whether new therapies can reduce alcohol intake

This research reflects a growing focus on integrated care for patients with overlapping psychiatric and behavioral conditions.

Trials in congenital, hereditary, and neonatal diseases and abnormalities and related metabolic conditions include work on severe hypertriglyceridemia. The research aims to determine whether new therapies can more effectively lower triglyceride levels and improve lipid control in affected patients.

• Severe hypertriglyceridemia
• Evaluating treatments to lower fasting triglycerides
• Improving management of metabolic risk

These studies contribute to better understanding and treatment of lipid disorders that can increase broader health risks.

The site also supports trials in male urogenital diseases and cancer research, including studies in metastatic castration-resistant prostate cancer. The purpose is to evaluate new treatment combinations and identify biomarkers that may help guide more effective care.

• Metastatic castration-resistant prostate cancer
• Testing combination approaches for advanced cancer
• Exploring biomarkers linked to treatment response

This area of research aims to improve options for patients with advanced prostate cancer who have limited treatment choices.

Clinical research in skin and connective tissue diseases overlaps with autoimmune conditions such as psoriatic arthritis. These trials are focused on finding therapies that can better control both skin-related and joint-related disease activity while improving overall patient quality of life.

• Psoriatic arthritis with skin and joint involvement
• Testing therapies for symptom relief and disease control
• Supporting more personalized treatment selection

The research reflects a broad interest in inflammatory diseases that affect multiple body systems.

Across its 10 clinical trials, Frederiksberg Hospital brings together cardiovascular, immunology, psychiatric, and metabolic research. The overall aim is to test new therapies, improve understanding of disease mechanisms, and support more effective treatment decisions across several chronic conditions.

• Multiple chronic disease areas studied in one hospital setting
• Evaluating treatment effectiveness and symptom improvement
• Linking clinical outcomes with better disease understanding

This diverse portfolio highlights a strong commitment to both patient care and clinical innovation.